Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 6/20 | 1.00 |
| ▸ | POR | P16435 | 6/20 | 1.00 |
| ▸ | EED | O75530 | 4/20 | 0.54 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.54 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | NSD1 | Q96L73 | 2/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940235 | 0.93 | NQO1 (1.00) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL8189008 | 0.86 | NQO1 (0.75) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL28845339 | 0.82 | NQO1 (1.00) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL24119167 | 0.81 | NQO1 (0.68) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL5940262 | 0.81 | NQO1 (0.68) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL24119166 | 0.78 | NQO1 (0.72) | NQO1POREEDSUZ12EZH2 | |
| SCHEMBL12108763 | 0.73 | MAOA (0.73) | NQO1PORMAPTPOLBHSP90AA1 | |
| SCHEMBL14417735 | 0.71 | EED (0.71) | NQO1POREEDSUZ12EZH2 | |
| Tanshinone I SCHEMBL14993883 | 0.70 | TDP1 (1.00) | NQO1POREEDSUZ12EZH2 | |
| Tanshinone I SCHEMBL244391 | 0.70 | TDP1 (1.00) | NQO1POREEDSUZ12EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| WO-2009084834-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | MAZENCE INC. (KR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009082124-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE INC. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009048251-A2 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2009-04-16 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066294-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLE OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066301-A1 | ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066298-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | NQO1 892/4885POR 1162/4885EED 4627/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | NQO1 17/4885POR 3903/4885EED 3451/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | NQO1 260/4885POR 902/4885EED 4283/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | NQO1 250/4885POR 909/4885EED 4239/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | NQO1 773/4885POR 1472/4885EED 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.